Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-09-22

Clinical Trial Update: Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy of Faslodex (fulvestrant) for systemic lupus erythematosus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Faslodex (fulvestrant)

Snippet

Sponsor: The Center for Rheumatic Disease, Allergy, & Immunology | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED